Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Eli Lilly and Company
Hoffmann-La Roche
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
BioNTech SE
Taiho Oncology, Inc.
NRG Oncology
National Cancer Institute (NCI)
Prestige Biopharma Limited
Avistone Biotechnology Co., Ltd.
Checkpoint Therapeutics, Inc.
Novartis
Samsung Bioepis Co., Ltd.
EpicentRx, Inc.
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
Ionis Pharmaceuticals, Inc.
Radiation Therapy Oncology Group
Wake Forest University Health Sciences
CTI BioPharma
Celgene
Incyte Corporation
Institut Cancerologie de l'Ouest
Novartis
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Martha-Maria Krankenhaus Halle-Dölau gGmbH
University College, London
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Spectrum Pharmaceuticals, Inc
European Organisation for Research and Treatment of Cancer - EORTC
University College, London
The Norwegian Lung Cancer Study Group
Case Comprehensive Cancer Center
SCRI Development Innovations, LLC
National Cancer Institute (NCI)